Brief: Vyne Therapeutics Says Expects To Report Phase 2A Fmx114 Study Top Line Results In Q2 Of 2022

YARROW BIOSCIENCE

08/03/2022 20:21

March 8 (Reuters) - Vyne Therapeutics Inc  VYNE.O :
    * VYNE THERAPEUTICS - EXPECTS TO REPORT PHASE 2A FMX114
STUDY TOP
LINE RESULTS IN Q2 OF 2022, VERSUS PRIOR EXPECTATIONS OF THE Q1
2022
    * VYNE THERAPEUTICS- PHASE 2A FMX114 STUDY RESULTS DELAYED
MAINLY
DUE TO COVID-19-RELATED ENROLLMENT DELAYS IN AUSTRALIA, WHERE
STUDY IS BEING CONDUCTED

Source text for Eikon:  ID: 
Further company coverage:  VYNE.O 

 ((Reuters.Briefs@thomsonreuters.com;))